Edesa Biotech, Inc. (EDSA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-17.9%

$2.00

vs $2.44 price

Levered DCF

$1.90

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-8.05

Distress zone

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-1.94×	-2.31×	-1.51×	-0.77×	-6.68×	-10.91×	-9.1×	-17.58×
P/B	1.13×	7.18×	1.79×	1.44×	6.82×	7.62×	5.43×	2.39×
P/S	0×	0×	0×	0×	0×	211.15×	69.52×	127.32×
EV / EBITDA	-0.46×	-2.15×	-0.87×	-0.37×	-6.15×	-9.83×	-8.32×	-4.69×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	94.6%	75.3%	-110.2%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	-1946.7%	-689.3%	-2397.1%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	-1935.6%	-662.3%	-2378.6%
Current ratio	10.67×	0.91×	3.53×	4.25×	8.29×	5.3×	12.23×	21.6×
Debt / equity	0×	0.01×	0.01×	0×	0.01×	0.02×	0×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-57.7%	-311.4%	-118.8%	-186.9%	-102.2%	-69.9%	-51.8%	-44.6%
Return on invested capital	-63.5%	-350.6%	-129.1%	-194.3%	-179.3%	-68.8%	-52.8%	-45.0%
Return on assets	-53.1%	-161.8%	-94.2%	-151.6%	-91.5%	-59.1%	-47.6%	-42.8%
Free cash flow yield	-52.2%	-34.4%	-52.7%	-91.0%	-15.3%	-7.2%	-17.0%	-18.5%
Earnings yield	-51.3%	-43.4%	-66.4%	-130.0%	-15.0%	-9.2%	-9.5%	-18.7%
Enterprise value	$3.2M	$13.2M	$7.3M	$6.4M	$81.4M	$62.4M	$23.5M	$22.7M
Net debt / EBITDA	1.53×	0.17×	0.62×	0.4×	0.59×	1.11×	1.78×	0.87×
Cash conversion cycle (days)	0	0	0	0	-4,240	-30,182	-2,120	-150